Skip to main content

Table 1 Characteristics of the patients with IL28B C/C and IL28B T* genotypes.

From: The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

Characteristics IL28B C/C IL28B T* All HCV patients
Number of Patients 23 33 56
Sex-Female 6 (26.1%) 15 (45.5%) 21 (37.5%)
Age 49.9 ± 4.4 47.5 ± 6.7 48.52 ± 5.96
Race, African American (#) 1 (4.3%) 8 (24.2%) 9 (16.1%)
Cirrhosis 5(22.7%) 8(25.0%) 13 (24.1%)
Obesity 13(56.5%) 16(48.5%) 29(51.8%)
Diabetes mellitus 1(4.3%) 5(15.2%) 6(10.7%)
HCV genotype 1 16 (65.2%) 27 (81.8%) 43(76.8%)
Pretreatment ALT 96 ± 59 111 ± 79 104 ± 72
Pretreatment HCV RNA (IU/mL) 5,596,354 ± 6,524,048 4,424,606 ± 5,295,969 4,893,305 ± 5,788,661
High Viral Load (> 850,000 IU/mL) 17 (77.3%) 25 (75.8%) 42 (76.4%)
No Complete EVR (p < 4.27 e-05) 3 (13%) 22 (68.8%) 25 (45.5%)
No EVR (p < 0.005) 1 (4.3%) 12 (37.5%) 13 (26.3%)
Sustained Virologic Response (p < 0.0022) 15 (65.2%) 8 (24.2%) 23 (41.1%)